|
CO-ADMINISTRATION OF NSAIDS WITH A QUINOLONES MAY INCREASE THE RIKS OF CNS STIMULATION AND CONVULSIONS; THIS INTERACTION HAS NOT BEEN OBSERVED WITH MOXIFLOXACIN CLINICAL AND PRECLINICAL TRIALS
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
LITHIUM PLASMA LEVELS ARE RAISED BY THE DRUG
|
CO-ADMINISTRATION MAY INTERFERE WITH THE BENEFITS OF ASPIRIN TAKEN FOR HEART DISEASE, SHOULD BE TAKEN ON DIFFERENT TIMES
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
CO-ADMINISTRATION CAN BE ASSOCIATED WITH INCREASED OCCULT GASTROINTESTINAL BLOOD LOSS ; AT HIGH CONCENTRATION IN VITRO, CLOPIDOGREL INHIBITS P450IIC9, IT MAY INTERFERE WITH THE METABOLISM OF MANY NON-STEROIDAL ANTI-INFLAMMATORY AGENTS
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CONCOMITANT USE WITH PLATELET INHIBITORS, SUCH AS NSAIDS, MAY INCREASE THE RISK OF BLEEDING
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
CO-ADMINISTRATION WITH NSAIDS HAS RESULTED IN INCREASED BUN, SERUM CREATININE AND SERUM POTASSIUM LEVELS, AND WEIGHT GAIN
|
ANTICOAGULANT EFFECT IS INCREASED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS AND RENAL SIDE EFFECTS
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE INCIDENCE OF G.I. SIDE EFFECTS AND RENAL SIDE EFFECTS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
CO-ADMINISTRATION IN PATIENTS WITH COMPROMISED RENAL FUNCTION WHO ARE BEING TREATED WITH NSAIDS MAY RESULT IN A FURTHER DETERIORATION OF RENAL FUNCTION
|
INCREASED RISK OF NEPHROTOXICITY
|
CO-ADMINISTRATION OF ANTIPLATELET AGENTS WITH NSAIDS MAY BE ASSOCIATED WITH INCREASED INCIDENCE OF BLEEDING.
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
CO-ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY WITH ASPIRIN MAY INCREASE BLEEDING OR LEAD TO DECREASED RENAL FUNCTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY POSE INCREASED RISK OF HYPERKALEMIA & NEPHROTOXICITY
|
CO-ADMINISTRATION OF NSAIDS WITH QUINOLONES MAY INCREASE THE RISK OF CNS STIMULATION AND CONVULSIONS ; THESE EVENTS HAVE NOT BEEN OBSERVED WITH GATIFLOXACIN IN PRE-CLINICAL AND CLINICAL TRIALS
|
CO-ADMINISTRATION OF NSAIDS ELEVATE AND PROLONG SERUM METHOTREXATE CONCENTRATIONS RESULTING IN DEATHS FROM SEVERE HEMATOLOGIC AND GASTROINTESTINAL TOXICITY; CONCURRENT AND/OR SEQUENTIAL USE OF NSAIDS WITH HIGH DOSE METHOTREXATE SHOULD BE AVOIDED
|
KETOROLAC ASSOCIATED BLEEDING RISK IS INCREASED BY OTHER NSAIDS, ASPIRIN & BY PENTOXIPHYLLINE
|
NSAIDS CONCURRENT ADMINISTRATION MAY OCCASIONALLY CAUSE RENAL DYSFUNCTION
|